CompletedNCT00292409
Official study titleA Prospective Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT00156637
Official study titleA Study of Strategies to Improve Schizophrenia Treatment
This study has finished and is no longer accepting participants.
Multiple locations, including FayettevilleSchizophreniaBehavioural studyAges 18–65
- Countries
- United States
- Sponsor
- US Department of Veterans Affairs
CompletedNCT03751488
Official study titleA Randomized, Single-Dose, Open-Label, Parallel-Group Study to Determine the Relative Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Luye Pharma Group Ltd.
CompletedNCT01193153
Official study titleA Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveSchizophreniaMedication studyAges 18–65
- Countries
- United States, Bulgaria, India, + 5 others
- Sponsor
- Janssen Scientific Affairs, LLC
CompletedNCT01292577
This study has finished and is no longer accepting participants.
In PittsburghSchizophreniaBehavioural studyAges 18–55
- Countries
- United States
- Sponsor
- University of Pittsburgh
CompletedNCT00222235
Official study titleCognitive and Negative Symptoms in Schizophrenia Trial (CONSIST)
This study has finished and is no longer accepting participants.
Multiple locations, including Los AngelesSchizophreniaMedication studyAges 18–54
- Countries
- United States, Israel
- Sponsor
- University of Maryland, Baltimore
CompletedNCT01822418
Official study titleAgomelatine Treatment of Major Depressive Episodes in the Course of Schizophrenic Psychoses (AGOPSYCH)
This study has finished and is no longer accepting participants.
In MannheimSchizophrenia, DepressionMedication studyAges 18–60
- Countries
- Germany
- Sponsor
- Central Institute of Mental Health, Mannheim
CompletedNCT00864825
Official study titleAllopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Bat YamSchizophreniaMedication studyAges 18–65
- Countries
- Israel, Romania
- Sponsor
- Sheba Medical Center
CompletedNCT00269919
What is this study about?Researchers studied Risperidone Long-Acting Injectable (RLAI) to find out how it affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
In SeoulSchizophreniaMedication studyAges 18–65
- Countries
- South Korea
- Sponsor
- Janssen Korea, Ltd., Korea
CompletedNCT01309373
Official study titleEpidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia (REINTEGRA Study)
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaObservational studyAges 18–65
- Countries
- Sponsor
- Janssen-Cilag, S.A.
TerminatedNCT00715377
This study ended early.
In TorontoSchizophreniaMedication studyAges 50+
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
TerminatedNCT01913327
Official study titleLocus Coeruleus Neuroimaging of Antipsychotic/Modafinil Interactions on Cognition in Schizophrenia
This study ended early.
In San FranciscoSchizophreniaMedication studyAges 18–40
- Countries
- United States
- Sponsor
- University of California, San Francisco